Clinical trial
Omalizumab to Treat Hyper-IgE (Job's) Syndrome
NCT00260702 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00260702 |
|---|---|
| Title | Omalizumab to Treat Hyper-IgE (Job's) Syndrome |
| Official title | Pilot Study of Omalizumab (Xolair) in Hyper IgE (Job's) Syndrome |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Hyper-IgE Syndrome, Job's Syndrome |
| Intervention type | Drug |
| Interventions | Omalizumab (Xolair) |
| Enrollment | 1 |
| Start date | Nov 24, 2005 |
| Primary completion | Mar 19, 2010 |
| Completion | Mar 19, 2010 |
| First posted | Dec 1, 2005 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: